We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antiinfective biotechs face partnering gap.
- Authors
Sheridan, Cormac
- Abstract
The article informs that two more major pharmaceutical groups, Aventis Pharma Ltd. and Bayer Corp. announced recently that their strategies no longer include a focus on antiinfectives--leading, in the case of Aventis, to the creation of a new spinout company, Novexel. Pharmaceutical withdrawal from antibiotic and antifungal drug development means that biotech companies, which are becoming increasingly responsible for the development pipeline, could find it difficult to find partners down the line. The two events that served to confirm the ongoing retreat of major pharmaceutical companies from the antiinfective drugs arena occurred on successive days.
- Subjects
BUSINESS partnerships; AVENTIS Pharma Ltd.; BAYER Corp.; DRUG development; DRUGS; PHARMACEUTICAL industry
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 2, p155
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0205-155